LENZ Therapeutics (LENZ) Long-Term Deferred Tax (2022 - 2023)
LENZ Therapeutics (LENZ) reported Long-Term Deferred Tax of $73.0 for Q4 2023, down 100.0% year-over-year from $39.3 million in Q4 2022, and down 100.0% on a QoQ basis from $39.3 million in Q4 2022.
LENZ Therapeutics (LENZ) has 2 years of Long-Term Deferred Tax data on file, last reported at $73.0 in Q4 2023.
- Quarterly Long-Term Deferred Tax fell 100.0% year-over-year to $73.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $73.0 (down 100.0% YoY) and the FY2023 annual result came in at $73.0, down 100.0% from the prior year.
- Long-Term Deferred Tax retreated to $73.0 in Q4 2023 per LENZ's latest filing, from $39.3 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $39.3 million in Q4 2022 and bottomed at $73.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 73.00 |
| Dec 31, 2022 | 39.29 Mn |